MedTrace Logo

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

NCT07018050 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-09-22

No results posted yet for this study

Summary

The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.

Conditions

Interventions

DRUG

QLS32015

QLS32015 will be administered subcutaneously

DRUG

Pomalidomide

Pomalidomide will be self-administered as a single dose orally

DRUG

Dexamethasone

Dexamethasone will be administered orally or intravenously

DRUG

QL2109 or Daratumumab

QL2109 or Daratumumab will be administered subcutaneously.

DRUG

Bortezomib

Bortezomib will be administered subcutaneously

DRUG

Lenalidomide

Lenalidomide will be self-administered as a single dose orally

Sponsors & Collaborators

  • Qilu Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-12
Primary Completion
2027-11-30
Completion
2028-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07018050 on ClinicalTrials.gov